Calithera Biosciences Inc Forecasted to Earn FY2022 Earnings of $0.80 Per Share (CALA)

Calithera Biosciences Inc (NASDAQ:CALA) – Equities researchers at William Blair issued their FY2022 earnings estimates for Calithera Biosciences in a research report issued to clients and investors on Tuesday. William Blair analyst M. Phipps expects that the biotechnology company will post earnings per share of $0.80 for the year.

Calithera Biosciences (NASDAQ:CALA) last posted its quarterly earnings results on Thursday, November 2nd. The biotechnology company reported ($0.17) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.23) by $0.06. The business had revenue of $7.20 million for the quarter, compared to the consensus estimate of $6.02 million.

A number of other research firms also recently weighed in on CALA. Zacks Investment Research raised shares of Calithera Biosciences from a “hold” rating to a “buy” rating and set a $19.00 price target for the company in a research note on Monday, November 6th. ValuEngine downgraded shares of Calithera Biosciences from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Finally, BidaskClub downgraded shares of Calithera Biosciences from a “sell” rating to a “strong sell” rating in a research note on Saturday, December 9th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company’s stock. Calithera Biosciences presently has a consensus rating of “Hold” and a consensus target price of $17.20.

Calithera Biosciences (NASDAQ CALA) traded up $0.25 on Wednesday, hitting $7.30. 746,180 shares of the company were exchanged, compared to its average volume of 457,689. The company has a market capitalization of $264.30, a P/E ratio of -7.02 and a beta of 2.57. Calithera Biosciences has a twelve month low of $6.57 and a twelve month high of $20.05.

Large investors have recently modified their holdings of the business. Legal & General Group Plc bought a new stake in Calithera Biosciences in the second quarter valued at approximately $120,000. Trexquant Investment LP bought a new stake in Calithera Biosciences in the third quarter valued at approximately $168,000. Voya Investment Management LLC bought a new stake in Calithera Biosciences in the second quarter valued at approximately $211,000. Cubist Systematic Strategies LLC increased its stake in Calithera Biosciences by 10.9% in the second quarter. Cubist Systematic Strategies LLC now owns 14,972 shares of the biotechnology company’s stock valued at $222,000 after purchasing an additional 1,472 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System bought a new stake in Calithera Biosciences in the third quarter valued at approximately $239,000. 72.54% of the stock is owned by hedge funds and other institutional investors.

WARNING: “Calithera Biosciences Inc Forecasted to Earn FY2022 Earnings of $0.80 Per Share (CALA)” was originally published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this article on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The original version of this article can be read at https://www.com-unik.info/2018/02/09/calithera-biosciences-inc-forecasted-to-earn-fy2022-earnings-of-0-80-per-share-cala.html.

Calithera Biosciences Company Profile

Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.

Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit